Protein C Levels in Disseminated Intravascular Coagulation and Thrombotic Thrombocytopenic Purpura: Its Correlation with Other Coagulation Parameters

 

PDF Download Buy Article Permissions and Reprints

Summary

Protein C was measured by means of enzyme-linked immunosorbent assay (ELISA) in plasmas from 58 normal subjects, 39 patients with disseminated intravascular coagulation (DIC) and 5 patients with thrombotic thrombocytopenic purpura (TTP). Protein C levels ranged from 69.7 to 163.6% (95% confidence limits) in normal subjects. In patients with DIC, protein C concentrations were significantly decreased, with a geometric mean value of 42.1%. Protein C concentration was positively correlated with plasma prothrombin, antithrombin III and serum pseudocholinesterase, and was negatively correlated with von Willebrand factor antigen (vWF: Ag) and vWF: Ag/factor VIII ratio. These findings suggest that low protein C concentrations in DIC mean a consumption of protein C probably due to its activation by thrombin and/or impaired liver synthetic function. In patients with TTP, protein C levels were normal with a geometric mean value of 116.7%, indicating that the pathophysiology of TTP is quite different from that of DIC.

• References

• 1 Stenflo J. A new vitamin K-dependent protein.Purification from bovine plasma and preliminary characterization. J Biol Chem 1976; 251: 355-363
  PubMedGoogle Scholar
• 2 Kisiel W, Ericsson LH, Davie EW. Proteolytic activation of protein C from bovine plasma. Biochemistry 1976; 15: 4893-4900
  CrossrefPubMedGoogle Scholar
• 3 Kisiel W. Human plasma protein C. Isolation, characterization and mechanism of activation by α-thrombin. J Clin Invest 1979; 64: 761-769
  CrossrefPubMedGoogle Scholar
• 4 Mammen EF, Thomas WR, Seegers WH. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II) or autoprothrombin II-A. Thrombos Diathes Haemorrh 1961; 05: 218-249
  PubMedGoogle Scholar
• 5 Esmon NT, Owen WG, Esmon CT. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J Biol Chem 1982; 257: 859-864
  PubMedGoogle Scholar
• 6 Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. Biochemistry 1977; 16: 5824-5831
  CrossrefPubMedGoogle Scholar
• 7 Marlar RA, Kleiss AJ, Griffin JH. Human protein C: Inactivation of factors V and VIII in plasma by the activated molecule. Ann NY Acad Sci 1981; 370: 303-310
  CrossrefPubMedGoogle Scholar
• 8 Marlar RA, Kleiss AJ, Griffin JH. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood 1982; 59: 1067-1072
  PubMedGoogle Scholar
• 9 Seegers WH, McCoy LE, Groben HD, Sakuragawa N, Agrawal BBL. Purification and some properties of autoprothrombin II-A. An anticoagulant perhaps also related to fibrinolysis. Thromb Res 1972; 01: 443-460
  CrossrefPubMedGoogle Scholar
• 10 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 1221-1228
  CrossrefPubMedGoogle Scholar
• 11 Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373
  CrossrefPubMedGoogle Scholar
• 12 Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemostas 1982; 48: 01-05
  PubMedGoogle Scholar
• 13 Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309: 340-344
  CrossrefPubMedGoogle Scholar
• 14 Bertina RM, Broekmans AW, Krommenhoek-van EsC, van Wijngaarden A. The use of a functional and immunologic assay for plasma protein C in the study of the heterogeneity of congenital protein C deficiency. Thromb Haemostas 1984; 51: 01-05
  PubMedGoogle Scholar
• 15 Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C, an antithrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982; 60: 261-264
  PubMedGoogle Scholar
• 16 Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982; 02: 463-467
  PubMedGoogle Scholar
• 17 Francis RB, Thomas W. Behaviour of protein C inhibitor in intravascular coagulation and liver disease. Thromb Haemostas 1984; 52: 71-74
  PubMedGoogle Scholar
• 18 Kobayashi N, Maekawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. Bibl Haematol 1983; 49: 265-275
  PubMedGoogle Scholar
• 19 Biggs R. Human blood coagulation, haemostasis and thrombosis. Blackwell Scientific; Oxford: 1976: 657-750
  Google Scholar
• 20 Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1977; 29 (Suppl. 124) 21-37
  PubMedGoogle Scholar
• 21 Takahashi H. Studies on the pathophysiology and treatment of von Willebrand’s disease. I. Spectrum of von Willebrand’s disease in Niigata. Acta Haematol Jpn 1981; 44: 154-164
  PubMedGoogle Scholar
• 22 Ødegard OR, Fagerhol MK. Heparin cofactor activity and antithrombin III concentration in plasma related to age and sex. Scand J Haematol 1976; 17: 258-262
  PubMedGoogle Scholar
• 23 Abildgaard U, Lie M, Ødegard OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977; 11: 549-553
  CrossrefPubMedGoogle Scholar
• 24 Friberger P, Knos M, Gustavsson S, Aurell L, Claeson G. Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis 1978; 07: 138-145
  PubMedGoogle Scholar
• 25 Matsuda T, Ogawara M, Miura R, Seki T, Matsumoto T, Teramura Y, Nakamura K. Selective determination of α₀₂-plasmin inhibitor activity in plasma using chromogenic substrate. Thromb Res 1984; 33: 379-388
  CrossrefPubMedGoogle Scholar
• 26 Vigano S, Mannucci PM, Solinas S, Bottasso B, Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57: 213-220
  CrossrefPubMedGoogle Scholar
• 27 Vellenga E, Mulder NH. Normal levels of antithrombin III in acute leukemia complicated by coagulopathy. Acta Haematol 1980; 63: 336-338
  CrossrefPubMedGoogle Scholar
• 28 Sié P, Letrenne E, Caranobe C, Genestal M, Cathala B, Boneu B. Factor II related antigen and antithrombin III as indicators of liver failure in consumption coagulopathy. Thromb Haemostas 1982; 47: 218-220
  PubMedGoogle Scholar
• 29 Rodeghiero F, Mannucci PM, Vigano S, Barbui T, Gugliotta L, Cortellaro M, Dini E. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984; 63: 965-969
  PubMedGoogle Scholar
• 30 Denson KWE. The ratio of factor VIII-related antigen and factor VIII biological activity as an index of hypercoagulability and intravascular clotting. Thromb Res 1977; 10: 107-119
  CrossrefPubMedGoogle Scholar
• 31 Emekli NB, Ultin ON. The protective effect of autoprothrombin II anticoagulant on experimental DIC formed elements. Haematologica 1980; 65: 644-651
  PubMedGoogle Scholar
• 32 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor: Purification from human plasma and characterization. J Biol Chem 1983; 258: 163-168
  PubMedGoogle Scholar
• 33 Suzuki K, Nishioka J, Kusumoto H, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem 1984; 95: 187-195
  CrossrefPubMedGoogle Scholar
• 34 Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest 1984; 74: 2033-2041
  CrossrefPubMedGoogle Scholar
• 35 Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine 1981; 60: 413-428
  CrossrefPubMedGoogle Scholar
• 36 Machin SJ. Thrombotic thrombocytopenic purpura. Br J Haematol 1984; 56: 191-197
  CrossrefPubMedGoogle Scholar
• 37 Remuzzi G, Misiani R, Mecca G, de Gaetano G, Donati MB. Thrombotic thrombocytopenic purpura – A deficiency of plasma factors regulating platelet-vessel-wall interaction?. N Engl J Med 1978; 299: 311
  PubMedGoogle Scholar
• 38 Chen YC, McLeod B, Hall ER, Wu KK. Accelerated prostacyclin degradation in thrombotic thrombocytopenic purpura. Lancet 1981; 02: 267-269
  PubMedGoogle Scholar
• 39 Lian ECY, Harkness DR, Byrnes JJ, Wallach H, Hunez R. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood 1979; 55: 333-338
  PubMedGoogle Scholar
• 40 Lian ECY, Mui PTK, Siddiqui FA, Chiu AYY, Shiu LLS. Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G. J Clin Invest 1984; 73: 548-555
  CrossrefPubMedGoogle Scholar
• 41 Moake JL, Rudy CK, Trall JH, Weinstein MJ, Colannino NM, Azocare J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435
  CrossrefPubMedGoogle Scholar
• 42 Jaffe EA, Nachman RL, Merskey C. Thrombotic thrombocytopenic purpura – a coagulation parameter in twelve patients. Blood 1973; 42: 499-507
  PubMedGoogle Scholar
• 43 Cuttner J. Thrombotic thrombocytopenic purpura: A ten-year experience. Blood 1980; 56: 302-306
  PubMedGoogle Scholar